Ki-67 Expression in Benign Odontogenic Tumors in Dakar: A Cross-Sectional Immunohistochemical Study
Expression Du Ki-67 Dans les Tumeurs Odontogènes Bénignes à Dakar : Une Étude Immunohistochimique Transversale
DOI:
https://doi.org/10.67260/hra.v4i11.8162Keywords:
benign odontogenic tumours, ameloblastoma, Ki-67, proliferation index, immunohistochemistry, implant-supported rehabilitationAbstract
RESUME
Contexte. Les tumeurs odontogènes bénignes sont des lésions d’évolution habituellement lente, dont le comportement biologique reste imprévisible ; certaines, notamment l’améloblastome, récidivent après exérèse. Le Ki-67, marqueur de prolifération cellulaire, est proposé comme indicateur d’agressivité, mais les données africaines sont rares. Objectif. Évaluer le profil d’expression du Ki-67 dans les tumeurs odontogènes bénignes à Dakar et discuter ses implications pour la chirurgie et la réhabilitation implantaire. Méthodes. Une étude transversale analytique a inclus de façon exhaustive 55 pièces opératoires de tumeurs odontogènes bénignes provenant de deux services d’odontologie de Dakar, entre janvier 2020 et juillet 2022. L’immunohistochimie utilisait l’anticorps monoclonal Ki-67 MM1 (Leica BIOSYSTEMS) sur des coupes de 3 µm. Le marquage était classé négatif, faible (0–7 %), modéré (8–15 %) ou intense (>15 %). Les associations ont été testées par le test du Chi² (seuil de significativité : 5 %) avec SPSS 20.0. Résultats. Les améloblastomes représentaient 50,9 % des cas (n = 28), les dysplasies cémento-osseuses 36,4 % (n = 20) et les odontomes complexes 12,7 % (n = 7). Le marquage Ki-67 était faible dans 87,3 % des tumeurs (n = 48) et négatif dans 12,7 % (n = 7), tous des odontomes complexes. Aucun marquage modéré ou intense n’a été observé. Le pourcentage de cellules marquées était inférieur à 1 % dans 74,6 % des cas (n = 41) et égal à 5 % dans 12,7 % (n = 7). L’expression du Ki-67 était significativement associée à la durée d’évolution (p = 0,004), à l’aspect radiographique (p = 0,030) et au type histologique (p = 0,030). Conclusion. Les tumeurs odontogènes bénignes étudiées présentaient un faible index de prolifération. Dans cette cohorte, le Ki-67 ne peut être retenu comme biomarqueur prédictif de la prolifération tumorale ou du risque de récidive. Aucune donnée ne permet d’établir un lien entre l’index Ki-67 et l’ostéointégration.
ABSTRACT
Background. Benign odontogenic tumors are typically slow-growing lesions with unpredictable biological behavior; some, particularly ameloblastoma, recur after excision. Ki-67, a cell proliferation marker, has been proposed as an indicator of aggressiveness, but African data are scarce. Objective. To assess Ki-67 expression in benign odontogenic tumors in Dakar and discuss its implications for surgery and implant rehabilitation. Methods. A cross-sectional analytical study exhaustively included 55 surgical specimens of benign odontogenic tumors from two odontology departments in Dakar between January 2020 and July 2022. Immunohistochemistry used the monoclonal Ki-67 MM1 antibody (Leica BIOSYSTEMS) on 3-µm sections. Staining was classified as negative, low (0–7%), moderate (8–15%), or intense (>15%). Associations were tested using the Chi-square test (significance level: 5%) with SPSS 20.0. Results. Ameloblastomas accounted for 50.9% of cases (n = 28), cemento-osseous dysplasia for 36.4% (n = 20), and complex odontomas for 12.7% (n = 7). Ki-67 staining was low in 87.3% of tumors (n = 48) and negative in 12.7% (n = 7), all complex odontomas. No moderate or intense staining was observed. The percentage of stained cells was less than 1% in 74.6% of cases (n = 41) and equal to 5% in 12.7% (n = 7). Ki-67 expression was significantly associated with lesion duration (p = 0.004), radiographic appearance (p = 0.030), and histological type (p = 0.030). Conclusion. The benign odontogenic tumors studied showed a low proliferation index. In this cohort, Ki-67 cannot be retained as a predictive biomarker of tumor proliferation or recurrence risk. No data support a link between Ki-67 index and osseointegration.
References
1. Diatta M, Gadji M, Dièmè MJ, et al. Study of Ki67 in odontogenic benign tumors. J Oral Med Oral Surg Oral Pathol Oral Radiol. 2023;9:75–81. doi:10.18231/j.jooo.2023.017
2. Salunkhe G, Issac AS, Jha RK, et al. Immunohistochemical evaluation of Ki-67 proliferation marker in various biological variants of ameloblastoma. Cureus. 2025;17. doi:10.7759/cureus.99979
3. Costa RV, Balbinot KM, da Silveira GCAR, et al. Prognostic value of the expression and localization of cell proliferation and apoptosis markers in unicystic ameloblastomas. Sci Rep. 2024;14:3856. doi:10.1038/s41598-024-54132-7
4. Purwoyudho IGPS, Kamadjaja DB, Danudiningrat RMCP, et al. The differences in expression of tumor marker KI-67 and proliferating cell nuclear antigen (PCNA) in ameloblastoma with histopathological subtypes follicular, plexiform, and mixed (follicular-plexiform). Eur J Dent. 2025;19:929–34. doi:10.1055/s-0044-1791220
5. Mourabit F, Boukhani ME, Aziz Z, et al. Therapeutic management of giant ameloblastomas. SAS J Med. 2025;11:29–32. doi:10.36347/sasjm.2025.v11i01.008
6. Ramos-Santillan V, Oshi M, Nelson E, et al. High Ki67 gene expression is associated with aggressive phenotype in hepatocellular carcinoma. World J Oncol. 2024;15:257–67. doi:10.14740/wjon1751
7. D'Amario M, Pizzolante T, Magnacca C, et al. Ki67 as a proliferation marker: a study on odontogenic keratocysts and radicular cysts. J Stomatol Oral Maxillofac Surg. 2025;126:102313. doi:10.1016/j.jormas.2025.102313
8. AlSheddi MA. Immunohistochemical investigation of the proliferative activity of odontogenic cysts and tumors. Appl Immunohistochem Mol Morphol. 2024;33:111–6. doi:10.1097/pai.0000000000001240
9. Robinson L, Smit C, van Heerden MB, et al. Investigating the role of DNA ploidy and proliferation index in distinguishing ameloblastoma from ameloblastic carcinoma. Head Neck Pathol. 2025;19:13. doi:10.1007/s12105-024-01742-2
10. Panakkal PP, Matthews PN, Susan S, et al. The enigmatic odontogenic keratocyst: a cross-sectional study of odontogenic cysts and tumors using Ki-67. Rambam Maimonides Med J. 2025;16. doi:10.5041/rmmj.10549
11. Robinson L, Smit C, van Heerden MB, et al. Surrogate immunohistochemical markers of proliferation and embryonic stem cells in distinguishing ameloblastoma from ameloblastic carcinoma. Head Neck Pathol. 2024;18:92. doi:10.1007/s12105-024-01704-8
12. Costa RV, Balbinot KM, da Silveira GCAR, et al. Cell proliferation and apoptosis immunolocalisation suggest an association between aggressiveness and the preferred location of mural unicystic ameloblastomas: a multicentric study. Research Square. 2023. doi:10.21203/rs.3.rs-2652916/v1
13. Kumar SS, Pandey JK, Bharti S, et al. Analysis of the Ki-67 proliferation index in relation to tumor, node, and metastasis (TNM) stage in patients with oral cavity squamous cell carcinoma. Cureus. 2024;16. doi:10.7759/cureus.63751
14. Diatta M, Gadji M, Dièmè MJ, et al. Study of the cell proliferation index (Ki67) in inflammatory odontogenic cysts. Adv Oral Maxillofac Surg. 2023;11:100431. doi:10.1016/j.adoms.2023.100431
15. Rasul F, Saif R, Jehangir HM, et al. Clinicopathological features and expression of Ki-67 in odontogenic keratocyst, dentigerous cyst and radicular cyst. J Islamabad Med Dent Coll. 2023;12. doi:10.35787/jimdc.v12i1.869
16. Almeida LE, Lloyd DJ, Boettcher D, et al. Immunohistochemical analysis of dentigerous cysts and odontogenic keratocysts associated with impacted third molars—a systematic review. Diagnostics. 2024;14:1246. doi:10.3390/diagnostics14121246
17. Zubidi MA, Abdulhussain MM, Mohsin AS. Assessment of the relationship between Ki-67 expression and different clinicopathological factors of adenoid cystic carcinoma: a retrospective immunohistochemical study. Int J Biomed. 2025;15. doi:10.21103/article15(1)_oa14
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Zié Traore, Mamadou Diatta, Vazoumana Kouyate, Koffi François Kouadio, Mamadou Tamba, Chouaib Rifki

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License CC BY-NC-ND 4.0 that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work


















